In an unprecedented year, Lundbeck delivers sales growth of 4% and core EBIT of DKK 4.4 billion
HIGHLIGHTS Growth continues across all regions, with revenue reaching DKK 17,672 million in 2020, a growth of 4% in local currencies when compared to 2019. The newest product in the portfolio, Vyepti[®], continues to gain momentum doubling revenue in each quarter since launch, despite the pandemic’s negative impact on Health Care Provider (HCP) administered drugs. Cash flow presents a substantial improvement from last year. Growth continues to be driven by patient uptake due to the efficacy and reliability of the products in the portfolio, product launches in new markets and the